SECOND SUPPLEMENTAL INDENTURE


                       TENET HEALTHCARE CORPORATION, as Issuer


                                         AND


                                THE BANK OF NEW YORK,
                                      as Trustee




                             Dated as of August 21, 1997




                        Supplemental to Indenture, dated as of
                       March 1, 1995, relating to the Issuer's
                      10-1/8% Senior Subordinated Notes Due 2005




                                  TABLE OF CONTENTS
                                  -----------------

PARTIES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1

RECITALS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1

ARTICLE ONE -      DEFINITIONS AND OTHER GENERAL
                   PROVISIONS. . . . . . . . . . . . . . . . . . . . . . . . 2

    SECTION 1.1    Definitions . . . . . . . . . . . . . . . . . . . . . . . 2

    SECTION 1.2    Effect of Headings and Table of
                   Contents. . . . . . . . . . . . . . . . . . . . . . . . . 2

    SECTION 1.3    Successors and Assigns. . . . . . . . . . . . . . . . . . 2

    SECTION 1.4    Separability Clause . . . . . . . . . . . . . . . . . . . 2

    SECTION 1.5    Benefits of Second Supplemental
                   Indenture . . . . . . . . . . . . . . . . . . . . . . . . 3

    SECTION 1.6    Governing Law . . . . . . . . . . . . . . . . . . . . . . 3

    SECTION 1.7    Effectiveness . . . . . . . . . . . . . . . . . . . . . . 3

ARTICLE TWO   -    AMENDMENTS. . . . . . . . . . . . . . . . . . . . . . . . 3

    SECTION 2.1    Amendments to Section 1.01. . . . . . . . . . . . . . . . 3

    SECTION 2.2    Amendment to Section 1.02 . . . . . . . . . . . . . . . . 8

    SECTION 2.3    Amendment to Section 3.09 . . . . . . . . . . . . . . . . 8

    SECTION 2.4    Amendment to Section 4.07 . . . . . . . . . . . . . . . . 8

    SECTION 2.5    Amendment to Section 4.08 . . . . . . . . . . . . . . . .11

    SECTION 2.6    Amendment to Section 4.09 . . . . . . . . . . . . . . . .12

    SECTION 2.7    Amendment to Section 4.10 . . . . . . . . . . . . . . . .15

                                          i


    SECTION 2.8    Amendment to Section 4.16 . . . . . . . . . . . . . . . .15

    SECTION 2.9    Amendment to Section 11.02. . . . . . . . . . . . . . . .15

ARTICLE THREE -    NOTICE, ENDORSEMENT AND CHANGE OF FORM
                   OF SECURITIES . . . . . . . . . . . . . . . . . . . . . .16

    SECTION 3.1    Notice to Securityholders . . . . . . . . . . . . . . . .16

    SECTION 3.2    Notation on Securities. . . . . . . . . . . . . . . . . .16

SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .17

ACKNOWLEDGMENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18

                                          ii


         SECOND SUPPLEMENTAL INDENTURE, dated as of August 21, 1997 (the
"SECOND SUPPLEMENTAL INDENTURE"), between TENET HEALTHCARE CORPORATION, a Nevada
corporation (hereinafter called the "COMPANY"), and THE BANK OF NEW YORK, as
trustee (hereinafter called the "TRUSTEE"), under the Indenture (the
"INDENTURE"), dated as of March 1, 1995, between the Company and the Trustee
relating to the Company's 10-1/8% Senior Subordinated Notes Due 2005 (the
"SECURITIES").

                               RECITALS OF THE COMPANY

         WHEREAS, the Company proposes to amend (the "AMENDMENTS") the
Indenture to conform the restrictive covenants contained therein to those
contained in the Indenture, dated as of January 15, 1997, between the Company
and the Bank of New York, as Trustee, relating to the Company's 7 7/8% Senior
Notes due 2003, the Indenture, dated as of January 15, 1997, between the Company
and the Bank of New York, as Trustee, relating to the Company's 8% Senior Notes
due 2005, and the Indenture, dated as of January 15, 1997, between the Company
and the Bank of New York, as Trustee, relating to the Company's 8-5/8% Senior
Subordinated Notes due 2007.

         WHEREAS, the Company has solicited consents to the Amendments from the
holders of record of the Securities outstanding at the close of business on
August 7, 1997.

         WHEREAS, in accordance with Section 9.02 of the Indenture, the Holders
of a majority of the principal amount of the Securities then outstanding (other
than any Securities owned by the Company or any Affiliate of the Company) have
consented to such Amendments.

         WHEREAS, the Board of Directors of the Company has duly authorized the
execution and delivery of this Second Supplemental Indenture, the Company has
delivered an Officers' Certificate and an Opinion of Counsel to the Trustee
pursuant to Section 9.06 of the Indenture and the Company has done all other
things necessary to make this Second Supplemental Indenture a valid agreement of
the Company in accordance with the terms hereof and of the Indenture.

         NOW THEREFORE, the Company and Trustee agree as follows for the
benefit of the other party and for the equal and ratable benefit of the Holders
of the Securities:



                                      ARTICLE I

                           DEFINITIONS AND OTHER PROVISIONS
                                OF GENERAL APPLICATION

         SECTION 1.1    DEFINITIONS.

         For all purposes of the Indenture and this Second Supplemental
Indenture, except as otherwise expressly provided or unless the context
otherwise requires:

              (1)  the words "herein," "hereof" and "hereunder" and other words
    of similar import refer to the Indenture and this Second Supplemental
    Indenture as a whole and not to any particular Article, Section or
    subdivision; and

              (2)  certain capitalized terms used but not defined herein shall
    have the meanings assigned to them in the Indenture.

         SECTION 1.2    EFFECT OF HEADINGS AND TABLE OF CONTENTS.

         The Article and Section headings and the Table of Contents of this
Second Supplemental Indenture are for convenience only and shall not affect the
construction hereof.  Except as otherwise specifically set forth herein, all
references to Sections in the Indenture shall remain unchanged.

         SECTION 1.3    SUCCESSORS AND ASSIGNS.

         All covenants and agreements in this Second Supplemental Indenture by
the Company shall bind its successors and assigns, or any other obligor on the
Securities, whether expressed or not.

         SECTION 1.4    SEPARABILITY CLAUSE.

         In case any provision in this Second Supplemental Indenture shall be
invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby.


                                          2


         SECTION 1.5    BENEFITS OF SECOND SUPPLEMENTAL INDENTURE.

         Nothing in this Second Supplemental Indenture, express or implied,
shall give to any Person, other than the parties hereto and their successors
hereunder, any Paying Agent and the Holders, any benefit or any legal or
equitable right, remedy or claim under this Second Supplemental Indenture.

         SECTION 1.6    GOVERNING LAW.

         This Second Supplemental Indenture shall be governed by and construed
in accordance with the laws of the State of New York and all rights and remedies
shall be governed by such law without reference to its conflict of laws
provision.

         SECTION 1.7    EFFECTIVENESS.

         This Second Supplemental Indenture shall take effect on the date (the
"EFFECTIVE DATE") that each of the following conditions shall have been
satisfied:

         (a)  the Trustee shall have received an Opinion of Counsel and an
Officers' Certificate from the Company each dated the Effective Date and in
accordance with Section 8.06 of the Indenture; and

         (b)  each of the parties hereto shall have executed and delivered this
Second Supplemental Indenture.


                                      ARTICLE II

                                    THE AMENDMENTS

         SECTION 2.1    AMENDMENTS TO SECTION 1.01.

         (a)  The Definition of "ASSET SALE" in Section 1.01 of the Indenture
is hereby amended to read in its entirety as follows:

         ""ASSET SALE" means (i) the sale, lease, conveyance or other
    disposition of any assets (including, without limitation, by way of a sale
    and leaseback) other than in the ordinary course of business consistent


                                          3


    with past practices and (ii) the issuance or sale by the Company or any of
    its Subsidiaries of Equity Interests of any of the Company's Subsidiaries,
    in the case of either clause (i) or (ii), whether in a single transaction
    or a series of related transactions (a) that have a fair market value in
    excess of $25.0 million or (b) for net proceeds in excess of $25.0 million.
    Notwithstanding the foregoing: (a) a transfer of assets by the Company to a
    Subsidiary or by a Subsidiary to the Company or another Subsidiary, (b) the
    issuance of Equity Interests by a Subsidiary to the Company or to another
    Subsidiary, (c) a Restricted Payment that is permitted by Section 3.07
    hereof and (d) a Hospital Swap shall not be deemed to be an Asset Sale."

         (b)  The definition of "EXISTING INDEBTEDNESS" in Section 1.01 of the
Indenture is hereby amended to read in its entirety as follows:

         ""EXISTING INDEBTEDNESS" means Indebtedness of the Company and its
    Subsidiaries (other than Indebtedness under the New Credit Facility) in
    existence on January 30, 1997, until such amounts are repaid, including all
    reimbursement obligations with respect to letters of credit outstanding as
    of January 30, 1997."

         (c)  The definition of "HOSPITAL" in Section 1.01 of the Indenture is
hereby amended to read in its entirety as follows:

         ""HOSPITAL" means a hospital, outpatient clinic, long-term care
    facility or other facility or business that is used or useful in or related
    to the provision of healthcare services."

         (d)  Section 1.01 of the Indenture is hereby amended by adding the
definition of "NEW CREDIT FACILITY" to read in its entirety as follows:

         ""NEW CREDIT FACILITY" means that certain Credit Agreement by and
    among the Company and Morgan Guaranty Trust Company of New York and the
    other banks that are party thereto, providing for $2.8 billion in aggregate
    principal amount of Indebtedness, including any related notes, instruments
    and agreements executed in connection therewith, and in each case as
    amended, modified, extended, renewed, refunded, replaced or refinanced, in
    whole or in part, from time to time."


                                          4


         (e)  The definition of "PERMITTED LIENS" in Section 1.01 of the
Indenture is hereby amended to read in its entirety as follows:

         ""PERMITTED LIENS" means (i) Liens in favor of the Company; (ii) Liens
    on property of a Person existing at the time such Person is merged into or
    consolidated with the Company or any Subsidiary of the Company or becomes a
    Subsidiary of the Company; PROVIDED that such Liens were in existence prior
    to the contemplation of such merger, consolidation or acquisition (unless
    such Liens secure Indebtedness that was incurred in connection with or in
    contemplation of such acquisition and is used to refinance tax-exempt
    Indebtedness) and do not extend to any assets or the Company or its
    Subsidiaries other than those of the Person merged into or consolidated
    with the Company or that becomes a Subsidiary of the Company; (iii) Liens
    on property existing at the time of acquisition thereof by the Company or
    any Subsidiary of the Company; PROVIDED that such Liens were in existence
    prior to the contemplation of such acquisition (unless such Liens secure
    Indebtedness that was incurred in connection with or in contemplation of
    such acquisition and is used to refinance tax-exempt Indebtedness); (iv)
    Liens to secure the performance of statutory obligations, tender, bid,
    performance, government contract, surety or appeal bonds or other
    obligations of a like nature incurred in the ordinary course of business;
    (v) Liens existing on January 30, 1997; (vi) Liens for taxes, assessments
    or governmental charges or claims that are not yet delinquent or that are
    being contested in good faith by appropriate proceedings promptly
    instituted and diligently concluded; PROVIDED that any reserve or other
    appropriate provision as shall be required in conformity with GAAP shall
    have been made therefor; (vii) other Liens on assets of the Company or any
    Subsidiary of the Company securing Indebtedness that is permitted by the
    terms hereof to be outstanding having an aggregate principal amount at any
    one time outstanding not to exceed 10% of the Stockholders' Equity of the
    Company; and (viii) Liens to secure Permitted Refinancing Indebtedness
    incurred to refinance Indebtedness that was secured by a Lien permitted
    hereunder and that was incurred in accordance with the provisions hereof;
    PROVIDED that such Liens do not extend to or cover any property or assets
    of the Company or any Subsidiary other than assets or property securing the
    Indebtedness so refinanced."

         (f) The definition of "PERMITTED REFINANCING INDEBTEDNESS" in Section
1.01 of the Indenture is hereby amended to read in its entirety as follows:


                                          5


         ""PERMITTED REFINANCING INDEBTEDNESS" means any Indebtedness of the
    Company or any of its Subsidiaries issued in exchange for, or the net
    proceeds of which are used solely to extend, refinance, renew, replace,
    defease, or refund, other Indebtedness of the Company or any of its
    Subsidiaries; PROVIDED, that, except in the case of Indebtedness of the
    Company issued in exchange for, or the net proceeds of which are used
    solely to extend, refinance, renew, replace, defease, or refund,
    Indebtedness of a Subsidiary of the Company: (i) the principal amount of
    such Permitted Refinancing Indebtedness does not exceed the principal
    amount of the Indebtedness so extended, refinanced, renewed, replaced,
    defeased or refunded (plus the amount of any premiums paid and reasonable
    expenses incurred in connection therewith); (ii) such Permitted Refinancing
    Indebtedness has a final maturity date later than the final maturity date
    of, and has a Weighted Average Life to Maturity equal to or greater than
    the Weighted Average Life to Maturity of, the Indebtedness being extended,
    refinanced, renewed, replaced, defeased or refunded; (iii) if the
    Indebtedness being extended, refinanced, renewed, replaced, defeased or
    refunded is subordinated in right of payment to the Securities, such
    Permitted Refinancing Indebtedness has a final maturity date later than the
    final maturity date of, and is subordinated in right of payment to, the
    Securities on subordination terms at least as favorable to the Holders of
    the Securities as those contained in the documentation governing the
    Indebtedness being extended, refinanced, renewed, replaced, defeased or
    refunded; (iv) such Indebtedness is incurred by the Company if the Company
    is the obligor on the Indebtedness being extended, refinanced, renewed,
    replaced, defeased or refunded; and (v) such Indebtedness is incurred by
    the Company or a Subsidiary if a Subsidiary is the obligor on the
    Indebtedness being extended, refinanced, renewed, replaced, defeased or
    refunded."

         (g)  The definition of "REFINANCING" in Section 1.01 of the Indenture
is hereby amended to read in its entirety as follows:

         ""REFINANCING" has the meaning ascribed to it in the Prospectus dated
    January 27, 1997 relating to the Senior Notes and the Senior Subordinated
    Notes."

         (h)  The definition of "RELATED BUSINESS" in Section 1.01 of the
Indenture is hereby amended to read in its entirety as follows:


                                          6


         ""RELATED BUSINESS" means a healthcare business affiliated or
    associated with a Hospital or any business related or ancillary to the
    provision of healthcare services or information or the investment in
    management, leasing or operation of a Hospital."

         (i)  The definition of "SENIOR NOTES" in Section 1.01 of the Indenture
is hereby amended to read in its entirety as follows:

         ""SENIOR NOTES" means the 7 7/8% Senior Notes due 2003 and the 8%
    Senior Notes due 2005 of the Company in an aggregate principal amount of
    $1.3 billion, issued pursuant to the indentures dated as of January 15,
    1997 between the Company and the Bank of New York, as trustee, as amended
    or supplemented from time to time."

         (j)  Section 1.01 of the Indenture is hereby amended by adding the
definition of "SENIOR SUBORDINATED NOTES" to read in its entirety as follows:

         ""SENIOR SUBORDINATED NOTES" means the 85/8% Senior Subordinated Notes
    due 2007 of the Company in an aggregate principal amount of $700.0 million,
    issued pursuant to the Senior Subordinated Note Indenture."

         (k)  Section 1.01 of the Indenture is hereby amended by adding the
definition of "SENIOR SUBORDINATED NOTE INDENTURE" to read in its entirety as
follows:

         ""SENIOR SUBORDINATED NOTE INDENTURE" means the Indenture dated as of
    January 15, 1997 between the Company and The Bank of New York, as trustee,
    as amended or supplemented from time to time, under which the Senior
    Subordinated Notes were issued."

         (j)  Section 1.01 of the Indenture is hereby amended by adding the
definition of "SPECIFIED EXCHANGE" to read in its entirety as follows:

         ""SPECIFIED EXCHANGE" means any retirement of Indebtedness upon the
    exercise by a holder of such Indebtedness, pursuant to the terms thereof,
    of any right to exchange such Indebtedness for shares of common stock of
    Vencor, Inc. or any successor thereto or any other equity securities, other
    than Equity Interests of a Subsidiary, owned by the Company as of October
    11, 1995, or for any securities or other property received


                                          7


    with respect to such common stock or equity securities or cash in lieu
    thereof, whether or not such right is subject to the Company's ability to
    pay an amount in cash in lieu thereof."

         (k)  Section 1.01 of the Indenture is hereby amended, by including the
following definitions at the end thereof:

         ""2005 EXCHANGEABLE SUBORDINATED NOTES" means the 6% Exchangeable
    Subordinated Notes due 2005 of the Company in an aggregate principal amount
    of $320.0 million, issued pursuant to the Indenture dated as of January 10,
    1996, between the Company and The Bank of New York, as trustee, as amended
    or supplemented from time to time."

         ""2005 SENIOR SUBORDINATED NOTES" means the 10-1/8% Senior Notes due
    2005 of the Company in an aggregate principal amount of $900.0 million,
    issued pursuant to the Indenture dated as of March 1, 1995, between the
    Company and The Bank of New York, as trustee, as amended or supplemented
    from time to time."

         SECTION 2.2    AMENDMENT TO SECTION 1.02.

         Section 1.02 of the Indenture is hereby amended to delete the
references therein to "Commencement Date," "Excess Proceeds," "Offer Amount,"
"Offer Period," "Purchase Price,"  and "Senior Asset Sale Offer."

         SECTION 2.3    AMENDMENT TO SECTION 3.09.

         Section 3.09 of the Indenture is hereby deleted in its entirety.

         SECTION 2.4    AMENDMENT TO SECTION 4.07.

         Section 4.07 of the Indenture is hereby amended to read in its
entirety as follows:

         "SECTION 4.07. LIMITATIONS ON RESTRICTED PAYMENTS.

         The Company shall not, and shall not permit any of its Subsidiaries
    to, directly or indirectly: (i) declare or pay any dividend or make any
    distribution on account of the Company's or any of its Subsidiaries' Equity
    Interests (other than (w) Physician Joint Venture Distributions, (x) divi-


                                          8


    dends or distributions payable in Qualified Equity Interests of the
    Company, (y) dividends or distributions payable to the Company or any
    Subsidiary of the Company, and (z) dividends or distributions by any
    Subsidiary of the Company payable to all holders of a class of Equity
    Interests of such Subsidiary on a PRO RATA basis); (ii) purchase, redeem or
    otherwise acquire or retire for value any Equity Interests of the Company;
    or (iii) make any principal payment on, or purchase, redeem, defease or
    otherwise acquire or retire for value any Indebtedness that is subordinated
    to the Securities, except at the original final maturity date thereof or
    pursuant to a Specified Exchange or the Refinancing (all such payments and
    other actions set forth in clauses (i) through (iii) above being
    collectively referred to as "RESTRICTED PAYMENTS"), unless, at the time of
    and after giving effect to such Restricted Payment (the amount of any such
    Restricted Payment, if other than cash, shall be the fair market value (as
    conclusively evidenced by a resolution of the Board of Directors set forth
    in an Officers' Certificate delivered to the Trustee within 60 days prior
    to the date of such Restricted Payment) of the asset(s) proposed to be
    transferred by the Company or such Subsidiary, as the case may be, pursuant
    to such Restricted Payment):

         (a)  no Default or Event of Default shall have occurred and be
    continuing or would occur as a consequence thereof; and

         (b)  the Company would, at the time of such Restricted Payment and
    after giving PRO FORMA effect thereto as if such Restricted Payment had
    been made at the beginning of the most recently ended four full fiscal
    quarter period for which internal financial statements are available
    immediately preceding the date of such Restricted Payment, have been
    permitted to incur at least $ 1.00 of additional Indebtedness pursuant to
    the Fixed Charge Coverage Ratio test set forth in the first paragraph of
    Section 4.09 hereof; and

         (c)  such Restricted Payment, together with the aggregate of all other
    Restricted Payments made by the Company and its Subsidiaries after March 1,
    1995 (excluding Restricted Payments permitted by clauses (ii), (iii) and
    (iv) of the next succeeding paragraph), is less than the sum of (1) 50% of
    the Consolidated Net Income of the Company for the period (taken as one
    accounting period) from the beginning of the first fiscal quarter
    commencing after March 1, 1995 to the end of the Company's most recently
    ended fiscal quarter for which internal financial statements


                                          9


    are available at the time of such Restricted Payment (or, if such
    Consolidated Net Income for such period is a deficit, less 100% of such
    deficit), PLUS (2) 100% of the aggregate net cash proceeds received by the
    Company from the issue or sale (other than to a Subsidiary of the Company)
    since March 1, 1995 of Qualified Equity Interests of the Company or of debt
    securities of the Company or any of its Subsidiaries that have been
    converted into or exchanged for such Qualified Equity Interests of the
    Company, PLUS (3) $20.0 million.

         If no Default or Event of Default has occurred and is continuing, or
    would occur as a consequence thereof, the foregoing provisions shall not
    prohibit the following Restricted Payments:

         (i)     the payment of any dividend within 60 days after the date of
                 declaration thereof, if at said date of declaration such
                 payment would have complied with the provisions hereof;

         (ii)    the payment of cash dividends on any series of Disqualified
                 Stock issued after the January 30, 1997 in an aggregate amount
                 not to exceed the cash received by the Company since January
                 30, 1997 upon issuance of such Disqualified Stock;

         (iii)   the redemption, repurchase, retirement or other acquisition of
                 any Equity Interests of the Company or any Subsidiary in
                 exchange for, or out of the net cash proceeds of, the
                 substantially concurrent sale (other than to a Subsidiary of
                 the Company) of Qualified Equity Interests of the Company;
                 PROVIDED that the amount of any such net cash proceeds that
                 are utilized for any such redemption, repurchase, retirement
                 or other acquisition shall be excluded from clause (c)(2) of
                 the preceding paragraph;

         (iv)    the defeasance, redemption or repurchase of subordinated
                 Indebtedness with the net cash proceeds from an incurrence of
                 Permitted Refinancing Indebtedness or in exchange for or out
                 of the net cash proceeds from the substantially concurrent
                 sale (other than to a Subsidiary of the Company) of Qualified
                 Equity Interests of the Company; PROVIDED that the amount of
                 any such net cash proceeds that are utilized for


                                          10


                 any such redemption, repurchase, retirement or other
                 acquisition shall be excluded from clause (c)(2) of the
                 preceding paragraph;

         (v)     the repurchase, redemption or other acquisition or retirement
                 for value of any Equity Interests of the Company or any
                 Subsidiary of the Company held by any member of the Company's
                 (or any of its Subsidiaries') management pursuant to any
                 management equity subscription agreement or stock option
                 agreement; PROVIDED that the aggregate price paid for all such
                 repurchased, redeemed, acquired or retired Equity Interests
                 shall not exceed $15.0 million in any twelve-month period; and

         (vi)    the making and consummation of a Change of Control Offer with
                 respect to the Senior Subordinated Notes, the 2005 Senior
                 Subordinated Notes or the 2005 Exchangeable Subordinated Notes
                 in accordance with the provisions of the indentures relating
                 thereto.

         Not later than the date of making any Restricted Payment, the Company
    shall deliver to the Trustee an Officers' Certificate stating that such
    Restricted Payment is permitted and setting forth the basis upon which the
    calculations required by this covenant were computed."

         SECTION 2.5    AMENDMENT TO SECTION 4.08.

         Section 4.08 of the Indenture is hereby amended to read in its
entirety as follows:

         "SECTION 4.08. LIMITATIONS ON DIVIDEND AND OTHER PAYMENT RESTRICTIONS
                        AFFECTING SUBSIDIARIES.

         The Company shall not, and shall not permit any of its Subsidiaries
    to, directly or indirectly, create or otherwise cause or suffer to exist or
    become effective any consensual Transfer Restriction, except for such
    Transfer Restrictions existing under or by reason of:

         (a)  Existing Indebtedness as in effect on January 30, 1997,


                                          11


         (b)  this Indenture and the indentures related to the Senior Notes and
the Senior Subordinated Notes,

         (c)  applicable law,

         (d)  any instrument governing Indebtedness or Capital Stock of a
Person acquired by the Company or any of its Subsidiaries as in effect at the
time of such acquisition (except to the extent such Indebtedness was incurred in
connection with or in contemplation of such acquisition, unless such
Indebtedness was incurred in connection with or in contemplation of such
acquisition for the purpose of refinancing Indebtedness which was tax-exempt, or
in violation of Section 4.09 hereof), which encumbrance or restriction is not
applicable to any Person, or the properties or assets of any Person, other than
the Person, or the property or assets of the Person, so acquired, PROVIDED that
the Consolidated Cash Flow of such Person shall not be taken into account in
determining whether such acquisition was permitted by the terms hereof except to
the extent that such Consolidated Cash Flow would be permitted to be dividends
to the Company without the prior consent or approval of any third party,

         (e)  customary non-assignment provisions in leases entered into in the
ordinary course of business,

         (f)  purchase money obligations for property acquired in the ordinary
course of business that impose restrictions on the ability of any of the
Company's Subsidiaries to transfer the property so acquired to the Company or
any of its Subsidiaries,

         (g)  Permitted Refinancing Indebtedness, PROVIDED that the
restrictions contained in the agreements governing such Permitted Refinancing
Indebtedness are no more restrictive than those contained in the agreements
governing the Indebtedness being refinanced, or

         (h)  the New Credit Facility and related documentation as the same is
in effect on January 30, 1997 and as amended or replaced from time to time,
PROVIDED that no such amendment or replacement is more restrictive as to
Transfer Restrictions than the New Credit Facility and related documentation as
in effect on January 30, 1997."


                                          12


         SECTION 2.6    AMENDMENT TO SECTION 4.09.

         Section 4.09 of the Indenture is hereby amended to read in its
entirety as follows:

         "SECTION 4.09  LIMITATIONS ON INCURRENCE OF INDEBTEDNESS AND ISSUANCE
                        OF PREFERRED STOCK

         The Company shall not, and shall not permit any of its Subsidiaries
    to, directly or indirectly, create,  incur, issue, assume, Guarantee or
    otherwise become directly or indirectly liable, contingently or otherwise,
    with respect to (collectively, "INCUR") after January 30, 1997 any
    Indebtedness (including Acquired Debt), and the Company shall not issue any
    Disqualified Stock and shall not permit any of its Subsidiaries to issue
    any shares of preferred stock; PROVIDED, HOWEVER, that the Company may
    incur Indebtedness (including Acquired Debt) and the Company may issue
    shares of Disqualified Stock if the Fixed Charge Coverage Ratio for the
    Company's most recently ended four full fiscal quarters for which internal
    financial statements are available immediately preceding the date on which
    such additional Indebtedness is incurred or such Disqualified Stock is
    issued would have been at least 2.5 to l, determined on a PRO FORMA basis
    (including a PRO FORMA application of the net proceeds therefrom), as if
    the additional Indebtedness had been incurred or the Disqualified Stock had
    been issued, as the case may be, at the beginning of such four-quarter
    period.  Indebtedness consisting of reimbursement obligations in respect of
    a letter of credit shall be deemed to be incurred when the letter of credit
    is first issued.

         The foregoing provisions shall not apply to:

         (a)  the incurrence by the Company of Indebtedness pursuant to the New
Credit Facility in an aggregate principal amount at any time outstanding not to
exceed an amount equal to $2.8 billion less the aggregate amount of all
mandatory repayments applied to permanently reduce the commitments with respect
to such Indebtedness;

         (b)  the incurrence by the Company of Indebtedness represented by the
Securities, the Senior Notes and the Senior Subordinated Notes;


                                          13


         (c)  the incurrence by the Company and its Subsidiaries of the
Existing Indebtedness;

         (d)  the incurrence by the Company or any of its Subsidiaries of
Permitted Refinancing Indebtedness in exchange for, or the net proceeds of which
are used to extend, refinance, renew, replace, defease or refund, Indebtedness
that was permitted by this Indenture to be incurred (including, without
limitation, Existing Indebtedness);

         (e)  the incurrence by the Company of Hedging Obligations that are
incurred for the purpose of fixing or hedging interest rate or currency risk
with respect to any fixed or floating rate Indebtedness that is permitted by the
terms hereof to be outstanding or any receivable or liability the payment of
which is determined by reference to a foreign currency; PROVIDED that the
notional principal amount of any such Hedging Obligation does not exceed the
principal amount of the Indebtedness to which such Hedging Obligation relates;

         (f)  the incurrence by the Company or any of its Subsidiaries of
Physician Support Obligations;

         (g)  the incurrence by the Company or any of its Subsidiaries of
intercompany Indebtedness between or among the Company and any of its
Subsidiaries;

         (h)  the incurrence by the Company or any of its Subsidiaries of
Indebtedness represented by tender, bid, performance, government contract,
surety or appeal bonds, standby letters of credit or warranty or contractual
service obligations of like nature, in each case to the extent incurred in the
ordinary course of business of the Company or such Subsidiary;

         (i)  the incurrence by any Subsidiary of the Company of Indebtedness,
the aggregate principal amount of which, together with all other Indebtedness of
the Company's Subsidiaries at the time outstanding (excluding the Existing
Indebtedness until repaid or refinanced and excluding Physician Support
Obligations), does not exceed the greater of (1) 10% of the Company's
Stockholders' Equity as of the date of incurrence or (2) $10.0 million; PROVIDED
that, in the case of clause (l) only, the Fixed Charge Coverage Ratio for the
Company's most recently ended four full


                                          14


fiscal quarters for which internal financial statements are available
immediately preceding the date on which such Indebtedness is incurred would have
been at least 2.5 to 1, determined on a PRO FORMA basis (including a PRO FORMA
application of the net proceeds therefrom), as if such Indebtedness had been
incurred at the beginning of such four-quarter period; and

         (j)  the incurrence by the Company of Indebtedness (in addition to
Indebtedness permitted by any other clause of this covenant) in an aggregate
principal amount at any time outstanding not to exceed $250.0 million."

         SECTION 2.7    AMENDMENT TO SECTION 4.10.

         Section 4.10 of the Indenture is hereby deleted in its entirety.

         SECTION 2.8    AMENDMENT TO SECTION 4.16.

         Section 4.16 of the Indenture is amended by replacing the amount "$10
million" in the last sentence with the amount "$25 million".

         SECTION 2.9    AMENDMENT TO SECTION 11.02.

         The address of the Company in Section 11.02 of the Indenture is hereby
amended to read in its entirety as follows:

         "Tenet Healthcare Corporation
         3820 State Street
         Santa Barbara, California  93105
         Telecopier No.:  (805) 563-6846
         Attention:  Treasurer"



                                          15


                                     ARTICLE III

                 NOTICE, ENDORSEMENT AND CHANGE OF FORM OF SECURITIES

         SECTION 3.1    NOTICE TO SECURITYHOLDERS.

         After the Effective Date, the Company shall mail to Securityholders a
notice briefly describing the Amendments in accordance with Section 8.02 of the
Indenture.

         SECTION 3.2    NOTATION ON SECURITIES.

         Securities authenticated and delivered after the Effective Date shall,
at the Company's expense, be affixed by the Trustee with the following notation:

         "The Company and the Trustee have entered into a Second
    Supplemental Indenture, dated as of August 21, 1997, which amended
    certain covenants and eliminated the Company's obligation to offer to
    repurchase Securities with the proceeds from certain asset sales.
    Reference is hereby made to such Second Supplemental Indenture, copies
    of which are on file with The Bank of New York, as Trustee."

         The Trustee may, but shall not be required to, require holders of
Securities authenticated and delivered prior to the Effective Date to deliver
such Securities to the Trustee so that the Trustee may affix them with the
aforementioned notation.

                                      * * * * *


                                          16



         This Second Supplemental Indenture may be executed in counterparts,
each of which when so executed shall be deemed to be an original, but all such
counterparts shall together constitute but one and the same instrument.

Dated as of August 21, 1997

                                  TENET HEALTHCARE CORPORATION



                                  By: /s/ R. L. Mathiasen
                                      ------------------------
                                  Name: Raymond L. Mathiasen
                                  Title: Senior Vice President


                                  THE BANK OF NEW YORK,
                                       AS TRUSTEE



                                  By: /s/ Vivian Georges
                                      ------------------------
                                  Name: Vivian Georges
                                  Title: Assistant Vice President